Morgan Kevin, Stewart Alan J, Miller Nicola, Mullen Peter, Muir Morwenna, Dodds Michael, Medda Federico, Harrison David, Langdon Simon, Millar Robert P
Medical Research Council Human Reproductive Sciences Unit, Edinburgh Cancer Research Centre, Edinburgh, United Kingdom.
Cancer Res. 2008 Aug 1;68(15):6331-40. doi: 10.1158/0008-5472.CAN-08-0197.
Activation of gonadotropin-releasing hormone (GnRH) receptors inhibits proliferation of transformed cells derived from reproductive tissues and in transfected cell lines. Hence, GnRH receptors represent a therapeutic target for direct action of GnRH analogues on certain proliferating cells. However, more cell biological data are required to develop this particular application of GnRH analogues. Therefore, we compared the effects of GnRH receptor activation in transfected HEK293 cells (HEK293([SCL60])) with transfected human ovarian cancer cell lines SKOV3 and EFO21, human hepatoblastoma HepG2 cells, and rat neuroblastoma B35 cells. Marked differences in receptor levels, magnitude of inositol phosphate generation, and dynamics of inositol phosphate turnover occurred in the different cells. Activation of GnRH receptors, expressed at high or moderate levels, inhibited the growth of HEK293([SCL60]) and B35 cells, respectively. Western blotting detected markers of apoptosis [cleaved poly(ADP-ribose) polymerase, caspase-9] in HEK293([SCL60]) and B35 following treatment with 100 nmol/L d-Trp(6)-GnRH-I. Cell growth inhibition was partially or completely rescued with inhibitor Q-VD-OPh or Ro32-0432. Low levels of GnRH receptor expression in transfected SKOV3, EFO21, or HepG2 activated intracellular signaling but did not induce apoptosis or significantly affect cell proliferation. Tumor xenografts prepared from HEK293([SCL60]) regressed during treatment with d-Trp(6)-GnRH-I and growth of xenografts derived from transfected B35 was slowed. SKOV3 xenografts were not growth inhibited. Therefore, differences in levels of GnRH receptor and signaling differentially affect the apoptotic machinery within cell lines and contribute to the cell type-specific effects of GnRH on growth. Further studies should exploit the growth-inhibitory potential of GnRH receptor activation in abnormal cells in diseased human tissues.
促性腺激素释放激素(GnRH)受体的激活可抑制源自生殖组织的转化细胞以及转染细胞系中的细胞增殖。因此,GnRH受体是GnRH类似物对某些增殖细胞直接作用的治疗靶点。然而,开发GnRH类似物的这一特定应用还需要更多细胞生物学数据。因此,我们比较了转染的人胚肾293细胞(HEK293([SCL60]))与转染的人卵巢癌细胞系SKOV3和EFO21、人肝母细胞瘤HepG2细胞以及大鼠神经母细胞瘤B35细胞中GnRH受体激活的作用。不同细胞中受体水平、肌醇磷酸生成量以及肌醇磷酸周转动力学存在显著差异。高水平或中等水平表达的GnRH受体激活分别抑制了HEK293([SCL60])和B35细胞的生长。蛋白质免疫印迹法检测到在用100 nmol/L d-Trp(6)-GnRH-I处理后的HEK293([SCL60])和B35细胞中有凋亡标志物[裂解的聚(ADP-核糖)聚合酶、半胱天冬酶-9]。用抑制剂Q-VD-OPh或Ro32-0432可部分或完全挽救细胞生长抑制。转染的SKOV3、EFO21或HepG2细胞中低水平的GnRH受体表达激活了细胞内信号传导,但未诱导凋亡或显著影响细胞增殖。用d-Trp(6)-GnRH-I处理期间,由HEK293([SCL60])制备的肿瘤异种移植物消退,而源自转染的B35细胞的异种移植物生长减缓。SKOV3异种移植物未受到生长抑制。因此,GnRH受体水平和信号传导的差异对细胞系内的凋亡机制有不同影响,并导致GnRH对生长的细胞类型特异性作用。进一步的研究应利用GnRH受体激活在患病人体组织异常细胞中的生长抑制潜力。